Intellia Therapeutics Inc (NTLA)

Currency in USD
14.94
+0.16(+1.08%)
Closed·
14.940.00(0.00%)
·

Intellia Therapeutics Inc (NTLA) Earnings Dates & Reports

Latest Release
Feb 26, 2026
EPS / Forecast
-0.83 / -0.96
Revenue / Forecast
23.02M / 12.08M
EPS Revisions
Last 90 days
Release Date
Period End
EPS
/Forecast
Revenue
/Forecast
EPS Surprise %
Revenue Surprise %
Reaction
03/2026--/-0.914--/13.51M----Free Sign Up
12/2025-0.830/-0.96023.02M/12.08M+13.54%+90.56%Free Sign Up
09/2025-0.920/-1.0113.78M/14.06M+8.91%-1.99%Free Sign Up
06/2025-0.980/-1.0314.25M/11.99M+4.85%+18.85%Free Sign Up
03/2025-1.10/-1.2716.63M/12.79M+13.39%+30.02%Free Sign Up
12/2024-1.27/-1.3412.87M/9.28M+5.22%+38.69%Free Sign Up
09/2024-1.34/-1.399.11M/8.28M+3.6%+10.02%Free Sign Up
06/2024-1.52/-1.226.96M/19.68M-24.59%-64.63%Free Sign Up
03/2024-1.12/-1.3828.94M/10.65M+18.84%+171.74%Free Sign Up
12/2023-1.46/-1.44-1.92M/12.74M-1.39%-115.07%Free Sign Up

All numbers in USD

Intellia Therapeutics Inc Earnings Call Summary for Q4/2025

  • Q4 2025 EPS of -$0.83 beat forecast of -$0.96; revenue hit $23.02M vs. $12.08M expected, marking 90.56% surprise driven by collaborations.
  • R&D expenses dropped 24.1% YoY to $88.7M; net loss improved 25.6% to $95.8M as company optimizes costs ahead of lonvo-z commercial launch in 2027.
  • Cash position stands at $605.1M as of Dec 31, 2025, projected to fund operations into second half of 2027 amid restructuring efforts.
  • Stock rose 4.17% in pre-market trading; FY2026 EPS guidance ranges from -$0.95 to -$1.01 with continued revenue growth anticipated.
Last Updated: 02/26/2026, 09:20 AM
Read Full Transcript

FAQ

What Is Intellia Therapeutics Inc's Earnings Per Share (TTM)?

The Intellia Therapeutics Inc EPS (TTM) is -3.81.

When Is The Next Intellia Therapeutics Inc Earnings Date?

Intellia Therapeutics Inc will release its next earnings report on Apr 30, 2026.

What Is Intellia Therapeutics Inc’s Revenue Forecasts For Upcoming Quarters?

Intellia Therapeutics Inc’s revenue forecast is 13.51M.

How Did Intellia Therapeutics Inc React to the Company's Latest Earnings Report?

Intellia Therapeutics Inc reported a +13.54% EPS surprise and a +90.56% revenue surprise, comparing the latest report against analyst forecasts. The stock price changed by 2.68%, reflecting the market's response to the earnings results.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.